Newsletter Tool

Today’s Big News

Jun 27, 2025

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle

Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout

Teva’s CEO shares ‘Pivot to Growth’ progress

With thimerosal vote, Kennedy's ACIP shows willingness to take on vaccine conventions

Chutes & Ladders—Incyte taps new CEO after longtime leader hangs up his hat

Featured

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

By James Waldron

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

By Gabrielle Masson

Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases.

CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle

By Zoey Becker

Investors sued CytoDyn and former executives for allegedly misleading shareholders on the status of its potential treatment for HIV and COVID-19.

Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout

By Nick Paul Taylor

Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile end for a company that pulled in hundreds of millions of dollars from investors and partners.

Teva’s CEO shares ‘Pivot to Growth’ progress

By Ayla Ellison,Fraiser Kansteiner

In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead.

With thimerosal vote, RFK Jr.'s ACIP shows willingness to take on vaccine conventions

By Kevin Dunleavy

Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established vaccine practice, recommending against the use of flu shots that contain a preservative that has been used in shots for decades.

Chutes & Ladders—Incyte taps new CEO after longtime leader hangs up his hat

By Zoey Becker,Gabrielle Masson

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar commercial drugmaker it is today. Taking his place at the helm is Bill Meury, effective immediately.

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month

By Andrea Park

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, with Pride Month nearing its end, the vast majority have acknowledged the celebration in some way.

Fierce Pharma Asia—Vor-RemeGen, Otsuka-Harbour autoimmune deals; Datroway's lung cancer nod

By Angus Liu

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 bispecific from Harbour BioMed to develop against autoimmune diseases. AstraZeneca and Daiichi Sankyo's Datroway secured a lung cancer approval from the FDA. And more.

Fierce podcasts

Don’t miss an episode

Teva’s CEO shares ‘Pivot to Growth’ progress

In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead.

AbbVie, ADCs and the future of cancer care

Hype and hope for AI in rural healthcare

Resources

Executive Summary

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.